author_facet Abboud, Miguel R.
Yim, Eunsil
Adams, Robert J.
Abboud, Miguel R.
Yim, Eunsil
Adams, Robert J.
author Abboud, Miguel R.
Yim, Eunsil
Adams, Robert J.
spellingShingle Abboud, Miguel R.
Yim, Eunsil
Adams, Robert J.
Blood
The Progression and Development of Silent Infarcts in Children with Sickle Cell Anemia Is Prevented by Chronic Transfusions and Is Unrelated to Level of Hemolysis
Cell Biology
Hematology
Immunology
Biochemistry
author_sort abboud, miguel r.
spelling Abboud, Miguel R. Yim, Eunsil Adams, Robert J. 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood.v112.11.712.712 <jats:title>Abstract</jats:title> <jats:p>The risk for arterial strokes in children sickle cell disease can be predicted by measurement of cerebral blood velocity by transcranial dopppler ultrasonography (TCD) and decreased by institution of chronic transfusions. In the STOP II study, children with homozygous HbSS or HbSβ° with initial abnormal TCD who had been on chronic transfusion for at least 30 months and had normal TCD, while on transfusion, were randomized to either discontinue or remain on transfusions aimed at maintaining HbS levels below 30%. The patients were then followed for reversal back to abnormal TCD or the development of strokes. The study was stopped after 79 of a planned 100 patients were randomized as there were 16 events in patients randomized to discontinue transfusions as opposed to no events in patients randomized to the continue transfusion arm. Magnetic resonance imaging (MRI) was performed at base line before randomization, at the end of the study or at the time of suspected neurologic events, according to a standardized protocol. All images were reviewed for the presence size and location of ischemic lesions by experts unaware of the treatment assignment. Patients were stratified at randomization according to the presence or absence of ischemic lesions on MRI. We have analyzed data from the study to determine whether transfusion were effective in preventing the development and/or progression of silent ischemic lesions detected by MRI. Among the 79 patients in the study 21 (26.6%) had lesions while 58 (73.4%) had no MRI lesions at base line. At baseline there were no significant differences in age, hemoglobin, lactate dehydrogenase (LDH) levels and reticulocyte counts between patients with and without MRI lesions. Of the 58 patients with negative MRI 28 were randomized to the continue transfusion while 30 to the discontinue transfusions arms, reflecting the initial stratification. Their mean age was 12.6 and 11.6 years respectively. After a mean follow up time of 463.9 days 0/28 patients in the continue transfusion group as opposed to 6/30 patients, followed for a mean of 522 days, in the discontinue transfusion group developed new lesions (p=0.024). There were no significant differences in age, levels of hemoglobin, levels of fetal hemoglobin, LDH levels, reticulocyte count or bilirubin levels between the 6 patients who developed new lesions and the 24 who did not. Two of the six patients who developed new lesions also experienced a study end point and 4 did not. There was no correlation between the development of new lesions and initial abnormal TCD velocity in these 6 patients. When patients who either developed new lesions or had on increase in the total number of lesions were studied a total of 77 patients could be analyzed as 2 did not have follow up MRI. Fourteen patients were worse when compared to base line, 3/37 in the continue transfusion arm as opposed to 11/40 in the discontinue transfusion arm (p=0.03). There was no significant difference in age, hemoglobin level, LDH levels, reticulocyte count or fetal hemoglobin levels between the 11 patients who were worse compared to the 29 patients whose MRI remained unchanged while off transfusions. As expected, the majority of all ischemic lesions were distributed to the frontral and parietal white matter areas. We conclude that transfusions were protective against the development of silent infarcts in our selected subpopulation of sickle cell patients with abnormal cereberal blood velocity measured by TCD. Furthermore markers of increased hemolysis such as LDH, biluribin and reticulocyte counts were not associated with risk for the development of silent infarcts in our patients.</jats:p> The Progression and Development of Silent Infarcts in Children with Sickle Cell Anemia Is Prevented by Chronic Transfusions and Is Unrelated to Level of Hemolysis Blood
doi_str_mv 10.1182/blood.v112.11.712.712
facet_avail Online
Free
finc_class_facet Biologie
Medizin
Chemie und Pharmazie
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52MTEyLjExLjcxMi43MTI
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52MTEyLjExLjcxMi43MTI
institution DE-Gla1
DE-Zi4
DE-15
DE-Pl11
DE-Rs1
DE-105
DE-14
DE-Ch1
DE-L229
DE-D275
DE-Bn3
DE-Brt1
DE-D161
DE-Zwi2
imprint American Society of Hematology, 2008
imprint_str_mv American Society of Hematology, 2008
issn 0006-4971
1528-0020
issn_str_mv 0006-4971
1528-0020
language English
mega_collection American Society of Hematology (CrossRef)
match_str abboud2008theprogressionanddevelopmentofsilentinfarctsinchildrenwithsicklecellanemiaispreventedbychronictransfusionsandisunrelatedtolevelofhemolysis
publishDateSort 2008
publisher American Society of Hematology
recordtype ai
record_format ai
series Blood
source_id 49
title The Progression and Development of Silent Infarcts in Children with Sickle Cell Anemia Is Prevented by Chronic Transfusions and Is Unrelated to Level of Hemolysis
title_unstemmed The Progression and Development of Silent Infarcts in Children with Sickle Cell Anemia Is Prevented by Chronic Transfusions and Is Unrelated to Level of Hemolysis
title_full The Progression and Development of Silent Infarcts in Children with Sickle Cell Anemia Is Prevented by Chronic Transfusions and Is Unrelated to Level of Hemolysis
title_fullStr The Progression and Development of Silent Infarcts in Children with Sickle Cell Anemia Is Prevented by Chronic Transfusions and Is Unrelated to Level of Hemolysis
title_full_unstemmed The Progression and Development of Silent Infarcts in Children with Sickle Cell Anemia Is Prevented by Chronic Transfusions and Is Unrelated to Level of Hemolysis
title_short The Progression and Development of Silent Infarcts in Children with Sickle Cell Anemia Is Prevented by Chronic Transfusions and Is Unrelated to Level of Hemolysis
title_sort the progression and development of silent infarcts in children with sickle cell anemia is prevented by chronic transfusions and is unrelated to level of hemolysis
topic Cell Biology
Hematology
Immunology
Biochemistry
url http://dx.doi.org/10.1182/blood.v112.11.712.712
publishDate 2008
physical 712-712
description <jats:title>Abstract</jats:title> <jats:p>The risk for arterial strokes in children sickle cell disease can be predicted by measurement of cerebral blood velocity by transcranial dopppler ultrasonography (TCD) and decreased by institution of chronic transfusions. In the STOP II study, children with homozygous HbSS or HbSβ° with initial abnormal TCD who had been on chronic transfusion for at least 30 months and had normal TCD, while on transfusion, were randomized to either discontinue or remain on transfusions aimed at maintaining HbS levels below 30%. The patients were then followed for reversal back to abnormal TCD or the development of strokes. The study was stopped after 79 of a planned 100 patients were randomized as there were 16 events in patients randomized to discontinue transfusions as opposed to no events in patients randomized to the continue transfusion arm. Magnetic resonance imaging (MRI) was performed at base line before randomization, at the end of the study or at the time of suspected neurologic events, according to a standardized protocol. All images were reviewed for the presence size and location of ischemic lesions by experts unaware of the treatment assignment. Patients were stratified at randomization according to the presence or absence of ischemic lesions on MRI. We have analyzed data from the study to determine whether transfusion were effective in preventing the development and/or progression of silent ischemic lesions detected by MRI. Among the 79 patients in the study 21 (26.6%) had lesions while 58 (73.4%) had no MRI lesions at base line. At baseline there were no significant differences in age, hemoglobin, lactate dehydrogenase (LDH) levels and reticulocyte counts between patients with and without MRI lesions. Of the 58 patients with negative MRI 28 were randomized to the continue transfusion while 30 to the discontinue transfusions arms, reflecting the initial stratification. Their mean age was 12.6 and 11.6 years respectively. After a mean follow up time of 463.9 days 0/28 patients in the continue transfusion group as opposed to 6/30 patients, followed for a mean of 522 days, in the discontinue transfusion group developed new lesions (p=0.024). There were no significant differences in age, levels of hemoglobin, levels of fetal hemoglobin, LDH levels, reticulocyte count or bilirubin levels between the 6 patients who developed new lesions and the 24 who did not. Two of the six patients who developed new lesions also experienced a study end point and 4 did not. There was no correlation between the development of new lesions and initial abnormal TCD velocity in these 6 patients. When patients who either developed new lesions or had on increase in the total number of lesions were studied a total of 77 patients could be analyzed as 2 did not have follow up MRI. Fourteen patients were worse when compared to base line, 3/37 in the continue transfusion arm as opposed to 11/40 in the discontinue transfusion arm (p=0.03). There was no significant difference in age, hemoglobin level, LDH levels, reticulocyte count or fetal hemoglobin levels between the 11 patients who were worse compared to the 29 patients whose MRI remained unchanged while off transfusions. As expected, the majority of all ischemic lesions were distributed to the frontral and parietal white matter areas. We conclude that transfusions were protective against the development of silent infarcts in our selected subpopulation of sickle cell patients with abnormal cereberal blood velocity measured by TCD. Furthermore markers of increased hemolysis such as LDH, biluribin and reticulocyte counts were not associated with risk for the development of silent infarcts in our patients.</jats:p>
container_issue 11
container_start_page 712
container_title Blood
container_volume 112
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792324041988636689
geogr_code not assigned
last_indexed 2024-03-01T11:43:25.468Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=The+Progression+and+Development+of+Silent+Infarcts+in+Children+with+Sickle+Cell+Anemia+Is+Prevented+by+Chronic+Transfusions+and+Is+Unrelated+to+Level+of+Hemolysis&rft.date=2008-11-16&genre=article&issn=1528-0020&volume=112&issue=11&spage=712&epage=712&pages=712-712&jtitle=Blood&atitle=The+Progression+and+Development+of+Silent+Infarcts+in+Children+with+Sickle+Cell+Anemia+Is+Prevented+by+Chronic+Transfusions+and+Is+Unrelated+to+Level+of+Hemolysis&aulast=Adams&aufirst=Robert+J.&rft_id=info%3Adoi%2F10.1182%2Fblood.v112.11.712.712&rft.language%5B0%5D=eng
SOLR
_version_ 1792324041988636689
author Abboud, Miguel R., Yim, Eunsil, Adams, Robert J.
author_facet Abboud, Miguel R., Yim, Eunsil, Adams, Robert J., Abboud, Miguel R., Yim, Eunsil, Adams, Robert J.
author_sort abboud, miguel r.
container_issue 11
container_start_page 712
container_title Blood
container_volume 112
description <jats:title>Abstract</jats:title> <jats:p>The risk for arterial strokes in children sickle cell disease can be predicted by measurement of cerebral blood velocity by transcranial dopppler ultrasonography (TCD) and decreased by institution of chronic transfusions. In the STOP II study, children with homozygous HbSS or HbSβ° with initial abnormal TCD who had been on chronic transfusion for at least 30 months and had normal TCD, while on transfusion, were randomized to either discontinue or remain on transfusions aimed at maintaining HbS levels below 30%. The patients were then followed for reversal back to abnormal TCD or the development of strokes. The study was stopped after 79 of a planned 100 patients were randomized as there were 16 events in patients randomized to discontinue transfusions as opposed to no events in patients randomized to the continue transfusion arm. Magnetic resonance imaging (MRI) was performed at base line before randomization, at the end of the study or at the time of suspected neurologic events, according to a standardized protocol. All images were reviewed for the presence size and location of ischemic lesions by experts unaware of the treatment assignment. Patients were stratified at randomization according to the presence or absence of ischemic lesions on MRI. We have analyzed data from the study to determine whether transfusion were effective in preventing the development and/or progression of silent ischemic lesions detected by MRI. Among the 79 patients in the study 21 (26.6%) had lesions while 58 (73.4%) had no MRI lesions at base line. At baseline there were no significant differences in age, hemoglobin, lactate dehydrogenase (LDH) levels and reticulocyte counts between patients with and without MRI lesions. Of the 58 patients with negative MRI 28 were randomized to the continue transfusion while 30 to the discontinue transfusions arms, reflecting the initial stratification. Their mean age was 12.6 and 11.6 years respectively. After a mean follow up time of 463.9 days 0/28 patients in the continue transfusion group as opposed to 6/30 patients, followed for a mean of 522 days, in the discontinue transfusion group developed new lesions (p=0.024). There were no significant differences in age, levels of hemoglobin, levels of fetal hemoglobin, LDH levels, reticulocyte count or bilirubin levels between the 6 patients who developed new lesions and the 24 who did not. Two of the six patients who developed new lesions also experienced a study end point and 4 did not. There was no correlation between the development of new lesions and initial abnormal TCD velocity in these 6 patients. When patients who either developed new lesions or had on increase in the total number of lesions were studied a total of 77 patients could be analyzed as 2 did not have follow up MRI. Fourteen patients were worse when compared to base line, 3/37 in the continue transfusion arm as opposed to 11/40 in the discontinue transfusion arm (p=0.03). There was no significant difference in age, hemoglobin level, LDH levels, reticulocyte count or fetal hemoglobin levels between the 11 patients who were worse compared to the 29 patients whose MRI remained unchanged while off transfusions. As expected, the majority of all ischemic lesions were distributed to the frontral and parietal white matter areas. We conclude that transfusions were protective against the development of silent infarcts in our selected subpopulation of sickle cell patients with abnormal cereberal blood velocity measured by TCD. Furthermore markers of increased hemolysis such as LDH, biluribin and reticulocyte counts were not associated with risk for the development of silent infarcts in our patients.</jats:p>
doi_str_mv 10.1182/blood.v112.11.712.712
facet_avail Online, Free
finc_class_facet Biologie, Medizin, Chemie und Pharmazie
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52MTEyLjExLjcxMi43MTI
imprint American Society of Hematology, 2008
imprint_str_mv American Society of Hematology, 2008
institution DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-D161, DE-Zwi2
issn 0006-4971, 1528-0020
issn_str_mv 0006-4971, 1528-0020
language English
last_indexed 2024-03-01T11:43:25.468Z
match_str abboud2008theprogressionanddevelopmentofsilentinfarctsinchildrenwithsicklecellanemiaispreventedbychronictransfusionsandisunrelatedtolevelofhemolysis
mega_collection American Society of Hematology (CrossRef)
physical 712-712
publishDate 2008
publishDateSort 2008
publisher American Society of Hematology
record_format ai
recordtype ai
series Blood
source_id 49
spelling Abboud, Miguel R. Yim, Eunsil Adams, Robert J. 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood.v112.11.712.712 <jats:title>Abstract</jats:title> <jats:p>The risk for arterial strokes in children sickle cell disease can be predicted by measurement of cerebral blood velocity by transcranial dopppler ultrasonography (TCD) and decreased by institution of chronic transfusions. In the STOP II study, children with homozygous HbSS or HbSβ° with initial abnormal TCD who had been on chronic transfusion for at least 30 months and had normal TCD, while on transfusion, were randomized to either discontinue or remain on transfusions aimed at maintaining HbS levels below 30%. The patients were then followed for reversal back to abnormal TCD or the development of strokes. The study was stopped after 79 of a planned 100 patients were randomized as there were 16 events in patients randomized to discontinue transfusions as opposed to no events in patients randomized to the continue transfusion arm. Magnetic resonance imaging (MRI) was performed at base line before randomization, at the end of the study or at the time of suspected neurologic events, according to a standardized protocol. All images were reviewed for the presence size and location of ischemic lesions by experts unaware of the treatment assignment. Patients were stratified at randomization according to the presence or absence of ischemic lesions on MRI. We have analyzed data from the study to determine whether transfusion were effective in preventing the development and/or progression of silent ischemic lesions detected by MRI. Among the 79 patients in the study 21 (26.6%) had lesions while 58 (73.4%) had no MRI lesions at base line. At baseline there were no significant differences in age, hemoglobin, lactate dehydrogenase (LDH) levels and reticulocyte counts between patients with and without MRI lesions. Of the 58 patients with negative MRI 28 were randomized to the continue transfusion while 30 to the discontinue transfusions arms, reflecting the initial stratification. Their mean age was 12.6 and 11.6 years respectively. After a mean follow up time of 463.9 days 0/28 patients in the continue transfusion group as opposed to 6/30 patients, followed for a mean of 522 days, in the discontinue transfusion group developed new lesions (p=0.024). There were no significant differences in age, levels of hemoglobin, levels of fetal hemoglobin, LDH levels, reticulocyte count or bilirubin levels between the 6 patients who developed new lesions and the 24 who did not. Two of the six patients who developed new lesions also experienced a study end point and 4 did not. There was no correlation between the development of new lesions and initial abnormal TCD velocity in these 6 patients. When patients who either developed new lesions or had on increase in the total number of lesions were studied a total of 77 patients could be analyzed as 2 did not have follow up MRI. Fourteen patients were worse when compared to base line, 3/37 in the continue transfusion arm as opposed to 11/40 in the discontinue transfusion arm (p=0.03). There was no significant difference in age, hemoglobin level, LDH levels, reticulocyte count or fetal hemoglobin levels between the 11 patients who were worse compared to the 29 patients whose MRI remained unchanged while off transfusions. As expected, the majority of all ischemic lesions were distributed to the frontral and parietal white matter areas. We conclude that transfusions were protective against the development of silent infarcts in our selected subpopulation of sickle cell patients with abnormal cereberal blood velocity measured by TCD. Furthermore markers of increased hemolysis such as LDH, biluribin and reticulocyte counts were not associated with risk for the development of silent infarcts in our patients.</jats:p> The Progression and Development of Silent Infarcts in Children with Sickle Cell Anemia Is Prevented by Chronic Transfusions and Is Unrelated to Level of Hemolysis Blood
spellingShingle Abboud, Miguel R., Yim, Eunsil, Adams, Robert J., Blood, The Progression and Development of Silent Infarcts in Children with Sickle Cell Anemia Is Prevented by Chronic Transfusions and Is Unrelated to Level of Hemolysis, Cell Biology, Hematology, Immunology, Biochemistry
title The Progression and Development of Silent Infarcts in Children with Sickle Cell Anemia Is Prevented by Chronic Transfusions and Is Unrelated to Level of Hemolysis
title_full The Progression and Development of Silent Infarcts in Children with Sickle Cell Anemia Is Prevented by Chronic Transfusions and Is Unrelated to Level of Hemolysis
title_fullStr The Progression and Development of Silent Infarcts in Children with Sickle Cell Anemia Is Prevented by Chronic Transfusions and Is Unrelated to Level of Hemolysis
title_full_unstemmed The Progression and Development of Silent Infarcts in Children with Sickle Cell Anemia Is Prevented by Chronic Transfusions and Is Unrelated to Level of Hemolysis
title_short The Progression and Development of Silent Infarcts in Children with Sickle Cell Anemia Is Prevented by Chronic Transfusions and Is Unrelated to Level of Hemolysis
title_sort the progression and development of silent infarcts in children with sickle cell anemia is prevented by chronic transfusions and is unrelated to level of hemolysis
title_unstemmed The Progression and Development of Silent Infarcts in Children with Sickle Cell Anemia Is Prevented by Chronic Transfusions and Is Unrelated to Level of Hemolysis
topic Cell Biology, Hematology, Immunology, Biochemistry
url http://dx.doi.org/10.1182/blood.v112.11.712.712